Bone metabolic markers in bone metastasis of breast cancer

被引：7

作者：

Koizumi M. ^{[1
]}

Takahashi S. ^{[2
]}

Ogata E. ^{[3
]}

机构：

[1] Department of Nuclear Medicine, Cancer Institute Hospital, Toshima-ku, Tokyo 170-8455

[2] Department of Medical Oncology, Cancer Institute Hospital, Tokyo

[3] Department of Internal Medicine, Cancer Institute Hospital, Tokyo

来源：

International Journal of Clinical Oncology | 1999年 / 4卷 / 6期

关键词：

Bone formation markers; Bone metastasis; Bone resorption markers; Breast cancer;

D O I：

10.1007/s101470050080

中图分类号：

学科分类号：

摘要：

Background. The efficacy and cost-performance benefit of radionuclide bone scintigraphy in monitoring metastatic bone activity remain controversial. Bone metabolic markers are now expected to play a role in the diagnosis and follow-up of bone metastasis. Methods. We investigated several bone metabolic markers in patients with breast cancer. We measured three metabolic markers of bone resorption: pyridinoline cross-linked carboxy terminal telopeptide (ICTP), C-telopeptides of type I collagen (CTx), and the free form of deoxypyridinoline (fDPD), and four metabolic markers of bone formation: procollagen I carboxy terminal peptide (PICP), total alkaline phosphatase (Al-p), bone-specific alkaline phosphatase (BAl-p), and osteocalcin (BGP) in 210 patients without and 268 patients with bone metastasis. Patients without bone metastasis were analyzed in terms of menstruation status. Patients with bone metastasis were analyzed in terms of bone metastatic burden and tumor lesion 'condition' (ie, determination by X- ray and/or computed tomography and bone scan findings of new lesion, progression of disease, no change, improvement, and complete remission, according to the criteria of the International Unite Against Cancer). Results. In patients without bone metastasis, ICTP did not change with menopause. All markers other than ICTP were significantly elevated with menopause. In patients with bone metastasis, all markers, except for BGP, were significantly elevated according to metastatic bone tumor burden. Among the seven markers, ICTP showed the best receiver operating characteristic curves. ICTP also showed the best correlation to bone metastatic burden among the markers by Spearman's rank correlation coefficient. In patients stratified by 'condition', ICTP, CTx, fDPD, Al-p, and BAl-p showed significant elevation in patients with progression, new lesion, and no change, while PICP and BGP showed only minimal elevation in those patients. Conclusion. Bone metabolic markers, particularly ICTP, appear to be valuable for the diagnosis of bone metastasis from breast cancer.

引用

页码：331 / 337

页数：6

共 19 条

[1]

Tubiana-Hulin M., Incidence, prevalence and distribution of bone metastasis, Bone, 12, 1 SUPPL., pp. 9-10, (1991)

[2]

Pretz D.J., Powles T.J., Milan J., Et al., Detection of breast carcinoma metastases in bone: Relative merit of X-rays and skeletal scintigraphy, Lancet, 2, pp. 613-616, (1983)

[3]

Coleman R.E., Rubens R.D., Fogelman I., Reappraisal of the baseline bone scan in breast cancer, J Nucl Med, 29, pp. 1045-1049, (1988)

[4]

Coleman R.E., Houson S., James I., Et al., Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastastatic bone disease, Br J Cancer, 65, pp. 766-768, (1992)

[5]

Kylmala T., Tammela T.L.J., Risteli L., Et al., Type-I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer, Br J Cancer, 71, pp. 1061-1064, (1995)

[6]

Koizumi M., Yamada Y., Takiguchi T., Et al., Bone metabolic markers in bone metastasis, J Cancer Res Clin Oncol, 121, pp. 542-548, (1995)

[7]

Maeda H., Koizumi M., Yoshimura K., Et al., Correlation between metabolic markers and bone scan in prostatic cancer, J Urol, 157, pp. 539-543, (1997)

[8]

Blomqvist C., Risteli L., Risteli J., Et al., Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast cancer, Br J Cancer, 73, pp. 1074-1079, (1996)

[9]

Demers L.M., Costa L., Chinchilli V.M., Et al., Biochemical markers of bone turnover in patients with metastatic bone disease, Clin Chem, 41, pp. 1489-1494, (1995)

[10]

Robins S.P., Woitge H., Hesley R., Et al., Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption, J Bone Miner Res, 9, pp. 1643-1649, (1994)

← 1 2 →